Noxopharm Ltd - Abscopal Responses Achieved in Prostate Cancer

What happened?

What's happened?

Noxopharm Limited (ASX:NOX) today has released details of the radiographic review of its DARRT-1 clinical study.

What are the key highlights?

The review shows a major benefit from a combination of the company's Veyonda® and low-dose radiotherapy.
The rationale behind DARRT is the use of a low dose of radiation to trigger an immune response to the cancer in one particular tumour, with Veyonda® then promoting a generalised spread of that immune response to tumours elsewhere in the body.
An anti-cancer response in distant non-irradiated lesions is known as an ‘abscopal response’ and has become a major new direction in oncology, offering the ability to achieve a significant anti-cancer effect with low, well-tolerated doses of radiation.
Noxopharm is developing the DARRT treatment regimen as a means of converting palliative therapy(mainly radiotherapy) into a therapy delivering a meaningful therapeutic outcome in patients with end-stage cancer. The Company is starting with end-stage prostate cancer.

For further details, please see the announcement linked below.

CEO's summary

Graham Kelly CEO of Noxopharm Ltd has provided a statement.

Graham Kelly

CEO, Noxopharm Ltd

"This is an exciting outcome that vindicates our belief in the anti-cancer properties of Veyonda®. There is growing interest in using combination targeted radiotherapy and immunotherapy drugs such as checkpoint inhibitors, with reports of some abscopal responses being obtained in certain cancers such as breast, lung and urological cancers and melanoma. But to our knowledge, this is the first time that anyone has been able to obtain a meaningful abscopal response rate in prostate cancer. Prostate cancer has developed a reputation as a cancer with poor immune responsiveness, but this DARRT-1 data suggests that this isn’t the case. Today’s result positions Veyonda® at the forefront of this emerging area of oncology and suggests that we have an exciting new prospective treatment for end-stage prostate cancer.”